Trending Topics in Gastroenterology
Explore current gastroenterology questions, clinical answers, and emerging research by topic.
Explore current gastroenterology questions, clinical answers, and emerging research by topic.
Introduction: Perioperative chemotherapy is standard for locally advanced esophagogastric adenocarcinoma, yet many patients struggle to receive postoperative treatment after major surgery. Whether all patients need the adjuvant component...
Introduction: Paclitaxel remains an important second-line treatment for advanced gastric cancer, but intravenous administration requires infusion-centre visits and carries risks of neuropathy and hypersensitivity reactions. This phase III...
Introduction: Major cancer surgery triggers a substantial inflammatory response that may contribute to postoperative complications and delayed recovery. A single preoperative corticosteroid dose has therefore been proposed to...
Introduction Management of advanced gastroesophageal cancer has moved rapidly from a largely chemotherapy-based approach toward biomarker-driven treatment selection. HER2, PD-L1, mismatch-repair status/MSI, and CLDN18.2 can now determine first-line...
Introduction: Comprehensive genomic profiling (CGP) is increasingly used in gastrointestinal cancers to identify actionable molecular alterations and guide precision therapy. However, its real-world value depends not only on...
Introduction: Lynch syndrome carries a lifelong risk of developing cancers across multiple organs. While colorectal surveillance is well established, the effectiveness of broader multiorgan surveillance remains less certain....
Introduction: Durvalumab plus gemcitabine–cisplatin (CGD) is standard first-line therapy for advanced biliary tract cancer (BTC) based on TOPAZ-1. However, clinical trials exclude many patients encountered in everyday practice....
Introduction: Lymph node metastasis is a major prognostic factor in oesophagogastric adenocarcinoma (OGAC), but tumour-negative lymph nodes (LNneg) have received little attention. This analysis of two major Phase...
Introduction: First-line immunochemotherapy is now standard for advanced biliary tract cancer (BTC), but treatment responses vary widely. Most prognostic models rely on baseline information, ignoring how patients evolve...
Introduction: The Phase III NETTER-2 trial established ¹⁷⁷Lu-DOTATATE plus octreotide as an effective first-line therapy for advanced, well-differentiated, somatostatin receptor (SSTR)-positive higher-grade G2–G3 gastroenteropancreatic neuroendocrine tumors (GEP-NETs). This...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.